A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

Some of the best foods for supporting healthy cholesterol levels are budget-friendly pantry staples that are versatile and ...

Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated ...

High cholesterol is a risk factor for cardiovascular disease, raising your risk for heart attack and stroke. Adopting ...

Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase ...

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Losing weight may involve rewiring the gut and the brain at the same time. In a study of obese adults, an intermittent ...

Very high levels are even more dangerous than better-known risks for heart-attack and stroke. “In individuals who don’t have heart disease, it seems it is equivalent to having two other modifiable ...

Trump fires back at critics of his health ahead of his 80th birthday, citing a perfect cognitive test score and calling out ...

In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs). ≥90 percent mean LDL-C ...

Rezdiffra leads MASH as TAM expands; growth for 2–3 years but big competition risks. Click for more on MDGL here.